Microbial Bioburden on Oral Solid Dosage Forms

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-02-02-2002
Volume 26
Issue 2

Low levels of some microorganisms that are present in oral solid dosage forms are unlikely to present a risk to patients. The amount of water activity in these products can help determine when microbiological testing should be conducted.

External Link - article-9672.pdf

Articles in this issue
Using Earned-Value Analysis to Better Manage Projects
Microbial Bioburden on Oral Solid Dosage Forms
Overview of Technologies Supporting Security Requirements in 21 CFR Part 11, Part I
Modernizing Pharmaceutical Manufacturing
The Role of Computational Fluid Dynamics in the Pharmaceutical Industry
Available Guidance and Best Practices for Conducting Forced Degradation Studies
Outsourcing Outlook
Effect of Formulation and Process Variables on Matrix Erosion and Drug Release from a Multiunit Erosion Matrix of a Poorly Soluble Drug
Recent Videos
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Behind the Headlines episode 6
Behind the Headlines episode 5
Related Content
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Orexo and Abera Partner to Develop Nasal Powder Vaccines

Feliza Mirasol
December 20th 2024
Article

The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

Novo Nordisk to Establish New Production Facility for Rare Disease Therapies in Denmark with DKK 8.5 Billion Investment

Feliza Mirasol
December 17th 2024
Article

Novo Nordisk will use the DKK 8.5 billion (US$1.2 billion) to build a new modular and flexible production facility in Odense, Denmark, that will produce multiple products for rare diseases.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Novo Nordisk Gains Manufacturing Sites from Novo Holdings and Novavax while EC Approves Catalent Acquisition

Feliza Mirasol
December 11th 2024
Article

The European Commission has approved Novo Holdings' acquisition of Catalent, which includes the related sale of three manufacturing sites to Novo Nordisk, which is also acquiring the Czech Republic manufacturing site of Novavax for $200 million.

3D printed pills and drugs, future of medicine. 3D Printing Drugs In Pharmacies. Multi-colored, various drugs, pills, capsules. Pharmaceutical medical concept | Image Credit: © irissca - © irissca - stock.adobe.com

Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications

Gary Ritchie;Sharon Flank
December 10th 2024
Article

This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.